Please assess the completion status of the following clinical trial:

Trial Title: N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnose is histologically or cytologically proven (NSCLC,SCLC), malignant mesothelioma (histologically)~* at least 4 cycles of cisplatin are planned~* adequate renal function (creatinine clearance as calculated by Cockroft-Gault method \> 60 ml/min)~* Karnofsky performance score \> 60 %~* written informed consent~* patient must be able to comply with study measurements i.e. hospital visits for EMG and QoL assessments~* age ≥ 18 years~Exclusion Criteria:~* patients with pre-existing neuropathy~* patients not willing to stop earlier prescribed NAC~* patients not willing to stop vitamins E and A above daily advisory dosage~* uncontrolled metastasis in the central or peripheral nervous system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): N-Acetylcysteine
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).